Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tipranavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | PGA5 | P0DJD9 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CTSE | P14091 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipranavir SCHEMBL6957763 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL5414762 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL6953675 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL40629 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL29393318 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL7407890 | 1.00 | MLNR (1.00) | MLNRNR1I2ABCB11PGRCTSD | |
| Tipranavir SCHEMBL434955 | 0.99 | MLNR (0.99) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7398499 | 0.98 | MLNR (0.96) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7398500 | 0.98 | MLNR (0.96) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7401866 | 0.98 | MLNR (0.96) | MLNRNR1I2ABCB11PGRCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246125-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | 712 NORTH INC. | 2021-08-12 | — | — | US | claimed |
| US-20240041764-A1 | Sustained-Release Oral Fosamprenavir Formulation for Treatment of Reflux | N-ZYME BIOMEDICAL INC. (CA) | 2024-02-08 | — | — | US | disclosed |
| US-20230172846-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2023-06-08 | — | — | US | disclosed |
| US-20230078695-A1 | Aerosolized Formulations of HIV Protease Inhibitors for the Treatment of Airway Reflux | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | EIF2AK2, IRF3, IFNG | MLNR 4370/4885NR1I2 727/4885ABCB11 3192/4885 |
| US-20210246125-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | OPA1, OLA1, PITRM1 | MLNR 4622/4885NR1I2 2201/4885ABCB11 3758/4885 |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | MLNR 3396/4885NR1I2 3329/4885ABCB11 2686/4885 |
| US-20230172846-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | DSTN, FDFT1, DDHD2 | MLNR 3066/4885NR1I2 3489/4885ABCB11 1183/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | MLNR 4092/4885NR1I2 4255/4885ABCB11 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.